Just weeks after Quintiles announced plans to set up a new CRO based in Beijing came out another plans to open itsÂ fourth hubÂ in China with plans to hire 500 workers for a new business process outsourcing operation that will cater to a broad range of biopharma clients with a multilingual staff based in Dalian.
NC-based Quintiles plans to offer regional as well as global clients help with data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillance and back-office support, in addition to supporting clinical operations at study sites scattered through the region.
Quintiles anticipates growing the center to 500 staff in the next several years once all services are fully established. It will be the company’s fourth hub office in Greater China (in addition to Beijing, Shanghai and Hong Kong).
China has been one of the world’s top emerging markets for Big Pharma. And drug developers of every stripe have been eyeing the country’s growing outsourcing offerings as CROs flock to the region.
Quintiles is proud to be the Exclusive "Diamond Sponsor" at the 5th annual BioPharma Asia Convention 2012. If you would like to meet with their consultants and BD team to explore partnership opportunities, contact Rebecca Koh at email@example.com now to arrange a meeting today!
More about Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide.
Our Asia Pacific presence began in 1982; there are now more than 20 offices in 14 countries in the region, so we can find a multitude of ways to help you turn healthy ideas into healthy people. Working to find flexible ways to help you accelerate outcomes, offering both insight and action from strategic business consulting to operational delivery using our in region resources ranging from data management and cardiac safety to Central Labs in China, India and Singapore.
Voted 2010 Asia Pacific CRO of the Year by Frost & Sullivan we have built our reputation in the region on the quality and results we have delivered across 1,700 studies involving 230+ partner and 4,000+ non partner sites. Quintiles' combination of global, regional and local expertise across a range of therapeutic areas including oncology, vaccines, neurology and cardiovascular disease has never been more important. For more information, please visit www.quintiles.com.